THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 2 DATA

In Segment A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. More individuals will likely be enrolled within the determined monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 might be presented as "insert-on" therapy. In Segment C, membe